PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
PSI Webinar
Patient Engagement in Clinical Trials
Date for Webinar: Tuesday 13th June 2:30-3:30pm UK time
Patients have long been an important part of clinical drug development – without them, there would be no new medicines. Recently, there has been a fundamental shift in their involvement in the drug development process. Today, patients are highly active in engaging in discussions about their disease, what they look for in new treatments, and how clinical trials are designed and conducted.
Following on from the successful and thought-provoking presentation at last year’s PSI conference by Paul Wicks from PatientsLikeMe, this webinar will continue to explore the ways in which patients are influencing the design of new clinical trials. We have two speakers who bring different experience and perspectives on this subject:
Dr Cathy Emmas, Partnership Director, Patient Centricity, AstraZeneca
Title: Patient-centric medicines development – the value of online health communities
Abstract: How AstraZeneca’s collaboration with the PatientsLikeMe is accelerating our ability to generate the timely and relevant patient insight that enables informed decision making within our R&D programs. What patient-generated health data tells us about symptoms and outcomes that matter to patients. Optimisation of clinical trials from the patient perspective.
Biography: Cathy is the Partnership Director in AstraZeneca’s global Patient Centricity team where she leads a 5 year strategic collaboration with the PatientsLikeMe online health network. This alliance was established to accelerate our ability to generate the right patient insight that enables informed decision making within our R&D programs and shape healthcare delivery. In the first two years the collaboration has linked the experiences of over 70,000 patients into our lifecycle teams and patient preferences have helped shape 12 clinical studies across 7 diseases.
Professor Sue Pavitt, Dental Translational and Clinical Research Unit, University of Leeds
Title: Achieving Effective Patient Public Involvement in Clinical Trials: “No research about us without us”
Abstract: Patient public involvement in medicine research and development has gained significant momentum. Adopting a patient-centric approach in clinical trials and research is important to ensure new treatments embrace what is important to patients. Achieving effective Patient Public Involvement & Engagement (PPIE ) partnerships enhances the relevance of clinical research and improved likelihood of delivering patient benefits. PPI also contributes to the operational efficiency and success in clinical trial design, ethical approval, conduct and dissemination reach; collectively building cross sector communication and partnerships may enhance market head room long term. I will provide a background to patient public involvement and establishing effective partnerships and illustrative case examples that support patient awareness of their treatment options and healthcare choices. I will introduce EUPATI and its role in meeting the educational needs to deliver patient centric medicine R&D and facilitate partnerships between patients-academia and industry in clinical research. We are in an era of a paradigm shift in patient-centric clinical trials, by strategically bringing the patient lived experience to the forefront has the potential to change fundamentally how health care is practiced.
Biography: Sue Pavitt - Prof in Translational & Applied Health Research, University of Leeds. Her PhD was in Human Cancer Genetics and she had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. In 1998 she was appointed as the Founding Director of TayRen – the premier Scottish multidisciplinary Primary Care Research network and the academic focus of her career changed to applied health research. She became the Divisional Director at the Clinical Trials Research Unit, Leeds and has since gone on to Head the Division for Applied Health and Clinical Translation and is Director of the Dental Translation and Clinical Research Unit. She is a Specialty lead for the Oral & Dental Health National Institute of Health Research (NIHR) Clinical Research Network. She is Chair of Multiple Sclerosis Clinical Trials Network. She is a Board Member of the MRC-NIHR Efficacy & Mechanistic Evaluation and in this capacity evaluated clinical trial design. Her research portfolio spans several disease areas and is characterized by forging effective, multi-disciplinary research partnerships between clinicians, academics, sometimes industry and always patients; developing methodological sound projects that are patient-centric with research questions tailored to clinical priorities to maximize impact and patient benefit. Sue is passionate about patient involvement in research with >30 years’ experience. She is the Academic Lead for EUPATI-UK – European Patient Advocacy for Therapeutic Innovation- a pan-European Innovative Medicines Initiative, led by the European Patients' Forum, in partnership with patient organizations, universities, not-for-profit organizations and pharmaceutical companies. EUPATI’s goal is to increase capacities and capabilities of well-informed patients to be effective advocates/advisors in medicines research.
To access the recording, please visit the Video-on-Demand Library.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Develop your non-technical skills by reading The Art of Explanation by Ros Atkins and joining the Sept-Dec 2025 book club. You will be invited to join facilitated discussions of the concepts and ideas and apply skills from the book in-between sessions.
Our monthly webinar will allow attendees to gain practical knowledge and skills in Open-Source coding and tools, with a focus on applications in the pharmaceutical industry. The sessions will provide starting points in a number of areas, correct any common misconceptions and provide valuable resources for further learning.
Date: Tuesday 9th September 2025 Join us to hear Sofia Weigle and Weng-Kee Wong present their recent work.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
AI agents are large language models equipped with tools that can autonomously tackle challenging tasks. This talk will explore how generative AI agents can enable biomedical discovery.
The webinar is targeted at statisticians working in the pharmaceutical industry, and the objective is to 1) provide a basic understanding of IV methodology including how it relates to causal inference, and 2) present two inspirational pharma-relevant applications.
The morning will be dedicated to networking opportunities, helping attendees build connections with peers and professionals. In the afternoon, participants can attend a series of talks and/or workshops, including a career panel featuring speakers from both academia and industry, offering insights into various career paths. There will also be a statistical workshop and a potential poster session. To wrap up the day, we’re exploring interest in an informal after-work networking event for those keen to continue the conversation.
The Pre-Clinical Special Interest Group (SIG) Workshop 2025 will take place over two half-days on 7 - 8 October in Verona, Italy, bringing together experts from industry, academia, and regulatory institutions to discuss key challenges and innovations in pre-clinical research.
Four sessions will include ML foundation (including an introduction, data exploration for ML and dimensionality reduction and feature selection), Supervised learning (including support vector machines and model evaluation and interpretation), model optimization and unsupervised learning (including clustering) and advanced topics (including neural networks, deep learning and large language models).
Webinar dedicated to the topic of stability modelling; opportunity to hear from statisticians working in the CMC field, with open question and answers. Brought to you by the CMC Statistical Network Europe (CSNE) SIG.
The program will feature insightful sessions led by distinguished invited speakers, alongside a poster session showcasing the latest advancements in the field. Further details will be provided.
Date: Wednesday 5th November 2025 A careers talk about medical statistics and how it plays a crucial role in developing new medicines
Date: 19 November 2025 This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
As an Associate Director Biostatistics Early Development, you will be a key member of our biostatistics group, you will play a crucial role in the design, analysis, and interpretation of clinical trials for early development programs.
If you are passionate about biostatistics and real-world data, and are looking for an exciting opportunity to contribute to groundbreaking research, we encourage you to apply.
Are you passionate about making a difference in the world of healthcare? Novartis is seeking a dynamic and experienced professional to join our team in London at The Westworks.
As the Director of HTA Biostatistics & Medical Affairs, you will play a pivotal role in shaping the future of healthcare by providing strategic biostatistical leadership and expertise.
An exciting opportunity has arisen for a permanent Senior Medical Statistician & Statistical Programmer to join the UKCRC fully registered Derby Clinical Trials Support Unit (Derby CTSU).
As a Senior Principal Biostatistician, you will be responsible and accountable for all statistical work, both scientific and operational, for one or more assigned clinical trials
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
AWS Elastic Load Balancing (ELB) automatically distributes incoming web traffic across multiple servers or services hosted on AWS.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Cloudflare, Inc. | Session |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | Amazon Web Services, Inc. | 7 days |
Used by Target Group-based load balancers for session stickiness. | |||
| AWSALBCORS | psi.glueup.com | Amazon Web Services, Inc. | 7 days |
Maintains session stickiness and secure routing between the user and backend servers through AWS load balancing. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
